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Background: A heightened risk of stroke and death among octogenarians undergoing carotid artery stenting (CAS) has
been reported. The multicenter Carotid Revascularization Endarterectomy vs. Stent Trial (CREST) supported by the
National Institute of Neurological Disorders, National Institutes of Health, compares the efficacy of carotid endarter-
ectomy (CEA) and CAS in an ongoing clinical trial. This effort also includes a “lead-in” phase of symptomatic (>50%
stenosis) and asymptomatic (>70% stenosis) patients. The protocol calls for patients to receive aspirin and clopidogrel
before and 30-days after CAS and to be examined by a study neurologist preprocedure, at 24-hours, and at 30-day. The
occurrence of stroke and death was reviewed by an independent clinical events committee.
Methods: The association of age and periprocedural stroke and death was examined in 749 lead-in patients undergoing
CAS (30.7% symptomatic, 69.3% asymptomatic). Patients were separated into four age categories: less than 60, 60 to 69,
70 to 79, and 80 years or older, and the proportion of patients with stroke and death during the 30-day periprocedural
period was calculated for each category.
Results: An increasing proportion of patients suffered stroke and death with increasing age (P  .0006); 2 (1.7%) of 120
patients under age 60, 3 (1.3%) of 229 aged 60 to 69, 16 (5.3%) of 301 aged 70 to 79, and 12 (12.1%) of 99 patients aged
80 years and older. These increasingly high complication rates at older ages were not mediated by adjustment for
symptomatic status, use of antiembolic devices, gender, percentage of carotid stenosis, or the presence of distal arterial
tortuosity.
Conclusions: Interim results from the lead-in phase of CREST show that the periprocedural risk of stroke and death after
CAS increases with age in the course of a credentialing registry. This effect is not mediated by potential confounding
factors. Randomized trial data are needed to compare the CAS versus CEA periprocedural risk of stroke and death by age.
Pending results from randomized studies, care should be taken when CAS is performed in older patient populations.
(J Vasc Surg 2004;40:1106-11.)Major clinical trials have established efficacy for carotid
endarterectomy (CEA) in symptomatic and asymptomatic
extracranial carotid occlusive disease1-5; however, these
trials excluded octogenarians, presumably because of a
potential higher risk of perioperative complications. Many
observational surgical reports of CEA among octogenari-
ans6-14 have documented 30-day stroke and death rates for
this group that are not significantly different from those
associated with younger patients. In a statewide analysis of
CEA results,15 age was not associated with a heightened
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1106risk of stroke and death. Other multi-institutional and
Medicare analyses have, however, suggested an increased
risk for CEA among octogenarians.16,17 These latter con-
siderations have led to the inclusion of octogenarians as a
high-risk group for CEA in a recent randomized trial18
comparing CEA and carotid artery stenting (CAS). Al-
though one might intuitively consider the less-invasive
CAS procedure as applicable to this elderly group of pa-
tients, earlier clinical experience19,20 without the benefit of
embolic protection in all cases have reported higher com-
plication rates among octogenarians.
The Carotid Revascularization Endarterectomy vs
Stenting Trial (CREST) is an ongoing, randomized, con-
trolled, multicenter clinical trial in symptomatic patients
with extracranial carotid occlusive disease that is designed
to assess the differential efficacy of CEA and CAS in pre-
venting stroke, myocardial infarction, and death in the
30-day periprocedural period, and ipsilateral stroke over
the follow-up period.21 A lead-in phase of CREST was
designed to provide a credentialing period for CAS using
neuroprotection at all clinical centers.
The performance of CEA and CAS is influenced by the
operator’s experience and technique, patient selection, and
outcome ascertainment bias. CEA and CAS outcomes
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rigorous prospective multicentered protocol such as
CREST. This report reviews interim data from the CREST
lead-in phase on the 30-day stroke and death rates by age
groups and compares these rates with other clinical series
on CAS as well as CEA.
METHODS
Interventionalists were admitted to CREST based on
low morbidity and mortality after a review of cases by the
Interventional Management Committee (IMC, Table I).
All approved interventionalists whowere selected for device
training in CREST were competent and possessed accept-
able catheter and guidewire skills.22 During the CREST
lead-in phase, each interventionalist was asked to use the
study devices (ACCULINK stents, ACCUNET antiem-
bolic devices, Guidant, Santa Clara, Calif) to perform CAS
procedures in up to 20 patients.
The protocol was approved by the ethics committees of
all study institutions and administrative sites prior to
screening and enrollment of patients. Informed consent
was obtained from every potential subject prior to enroll-
ment.
Asymptomatic (stenosis 70%) and symptomatic (ste-
nosis  50%) patients aged 18 and older were eligible for
inclusion in the lead-in phase of CREST; there was no
upper age restriction. All CAS procedures were performed
under local anesthesia by using a standard CAS protocol
(Table II). Patients were to be treated with aspirin and
clopidogrel before and for 30-days after stenting, examined
by a neurologist preprocedure, at 24 hours, and at 30 days,
and evaluated with a National Institutes of Health Stroke
Scale. An independent clinical events committee evaluated
the occurrence of stroke and death. Narrative summaries of
all strokes and deaths were studied by a subset of the
authors and colleagues on the CREST IMC.
Stenosis severity was interpreted from the qualifying
angiograms by the investigators at the participating clinical
sites, and the qualifying and procedural angiograms were
forwarded to the Angiographic Core Lab (Boston, MA) for
an independent review by observers who were blinded to
the clinical site readings. Baselinemorphologic criteria were
Table I. CREST Interventional Management
Committee
Gary Roubin, MD, PhD – Committee Co-Chair
Robert Ferguson, MD – Committee Co-Chair
Stanley Barnwell, MD
Thomas G. Brott, MD
Elie Chakhtoura, MD
Jonathan Goldstein, MD
William Gray, MD
Robert W. Hobson II, MD
L. Nick Hopkins, MD
Barry Katzen, MD
Kenneth Rosenfield, MD
CREST, Carotid Revascularization Endarterectomy vs Stent Trial.used to assess lesion complexity (eg, calcification, angula-tion, thrombus, access tortuosity), and procedural compli-
cations (eg, reduced flow, dissections) were identified dur-
ing and after the procedure.
The two angiographic projections that demonstrated
the carotid stenosis in its sharpest and most severe narrow-
ings were digitized, and a validated, automated edge-de-
tection algorithm was applied to the digitized image
(CAAS Pie Medical, The Netherlands).23 An external ref-
erence object was used as the calibration source to obtain
absolute vessel diameters before and after carotid stent
placement. The parallel tract of the internal carotid artery
was used for the reference vessel diameter (RVD) (North
American Symptomatic Carotid Endarterectomy Trial cri-
teria),24 and the minimal lumen diameter (MLD) within
the carotid artery was identified for the calculation of the
percentage of diameter stenosis [% diameter stenosis 
(1–[MLD/RVD])  100] at baseline and after the stent
procedure. The most severe baseline percentage of diame-
ter stenosis from the two projections was reported.
Statistical analysis. Logistic regression was used to
compare the 30-day stroke and death rates between age
strata of less than 60 years, 60 to 69 years, 70 to 79 years,
and 80 years and older. Potential confounding factors of
symptomatic status (asymptomatic vs symptomatic), use of
a cerebral protection device, degree of carotid stenosis,
presence or absence of tortuosity, and gender were added
to the logistic model to assess if these factors mediated the
association between age and peri-procedural risk.
RESULTS
During the period January 2000 to March 2004,
Table II. Protocol for carotid artery stent procedures
● Preprocedural (48 hours): oral aspirin (325 mg once or twice
daily) and oral clopidogrel (75 mg, twice daily). Ticlopidine
(250 mg twice daily) is substituted if the patient is unable to
tolerate clopidogrel.
● Transfemoral approach.
● Heparinization to activated clotting time of 250-300 (with
introduction of an antiembolic device).
● 5F Vitek catheter for cannulation of aortic arch branches.
● 0.035-inch coated Terumo long-exchange guidewire to
external carotid artery.
● 6F guide sheath (100-cm length) to common carotid artery
proximal to lesion; occasional use of the 0.035-inch Amplatz
stiff guidewire is recommended to advance the Vitek catheter
or 6F guide sheath into the common carotid artery.
● 0.014-inch guidewire to cross common-internal carotid
stenosis and place an antiembolic device (ACCUNET System,
Guidant, Santa Clara, CA); 3- or 4-mm low-profile balloon for
predeployment dilatation as required.
● Deployment of a nitinol self-expanding stent (ACCULINK
System, Guidant, Santa Clara, CA).
● Poststent dilatation using 5.0- to 5.5-mm balloons.
● Intermittent hand-injection angiography during procedure;
utilize bony landmarks for balloon and stent placements.
● Use of femoral closure device as recommend by individual
interventionalists; aspirin is continued indefinitely, while
clopidogrel (or ticlopidine) is continued for a minimum of 2 to
4 weeks after CAS.CREST investigators treated 862 adult patients with CAS
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age and outcome data were available on 749, and we have
restricted our discussion to that subset of patients. These
CAS procedures with complete outcome data were per-
formed by 83 interventionalists from 51 sites. Baseline
clinical characteristics of octogenarians and younger pa-
tients are summarized in Table III. Prevalence of diabetes
mellitus, dyslipidemia, and smoking were higher among
younger patients. The average age was 69.5  4 (mean 
SD) years and 481 (64%) were men. These patients were
symptomatic (amaurosis fugax, transient ischemia attack,
or nondisabling stroke within the previous 180 days in the
distribution of the study artery) in 229 (30.7%) instances
and asymptomatic in the distribution of the study artery in
516 (69.3%) cases. It should be noted that the stent proce-
dure was performed without the use of an embolic protec-
tion device in 88 (11.9%) patients who were treated early in
the series, whereas 649 (88.1%) patients were subsequently
treated using the Guidant ACCUNET system. The use of
antiembolic devices was not recorded for 12 patients.
Technical success with the CAS procedures was
achieved in 746 (99.7%) of 749 procedures. By 30 days
postprocedure, 33 (4.4%) neurologic events (27 strokes
only) or deaths (3 stroke deaths, 3 nonstroke deaths) were
observed in all patients, including octogenarians; the rate
was 3.2% in younger patients. Data for death, stroke, and
stroke or death are summarized in Table IV. No significant
differences (P  .22) were noted in the overall 30-day
stroke and death rates between symptomatic (5.7%) and
asymptomatic (3.7%) patients.
A highly significant difference (P 0.0006) was noted
in the 30-day perioperative event rate with increasing age.
Two (1.7%) of 120 patients under 60 had events compared
with 3 (1.3%) of 229 patients aged 60 to 69, 16 (5.3%) of
301 patients aged 70 to 79, and 12 (12.1%) of 99 patients
80 years and older. Adjustment for symptomatic status, use
of antiembolic devices, severity of stenosis, or gender had
little impact on the estimated magnitude of the age effect.
These data are summarized in Table V.
Trends noted when angiograms among octogenarians
and younger patients were compared were, respectively,
degree of stenosis (73.5% vs 71.5%), minimal residual lu-
Table III. Baseline clinical characteristics, lead-in
patients by age groups (octogenarians vs non-
octogenarians)
Octogenarians
(%) n  99
Non-octogenarians
(%) n  650 P
Diabetes 15.2 33.2 .0003
Hypertension 85.9 84.2 .68
Dyslipidemia 71.7 83.9 .004
Previous CABG 26.3 25.9 .94
Current Smoker 3.0 18.3 .0001
Aortic/mitral valve
disease
5.1 4.3 .78
CABG, Coronary artery bypass grafting.men prior to CAS (1.19 mm vs 1.29 mm), and residualstenosis after CAS (12.6% vs 11.5%). None of these differ-
ences was significant, however.
Characteristics at the carotid bifurcation on multivari-
able analysis, including qualitative assessment of ulceration,
intraarterial thrombus, calcification, and the presence or
absence of tortuosity were not significantly different be-
tween the two age groups. However, tortuosity with angu-
lation of the distal carotid artery of 90 degrees or more was
reported in two octogenarians and was more common in
this age group (P .02). In these two patients, the severity
of tortuosity precluded the placement of an antiembolic
device and contributed to complications in oneof the patients.
Ten narrative summaries from the 12 complications
among the octogenarians were currently available for re-
view. Major stroke occurred in 6 patients, minor stroke in 4
patients, and 1 patient died. Transient hemodynamic insta-
bility (bradycardia and hypotension) at initiation of the
procedure or with balloon inflation was noted in 7 of the10
summaries. Although the neurologic complications re-
ported were not observed at the time of these transient
episodes, this may have ultimately contributed to the
higher incidence of neurologic events among octogenari-
ans. In two cases, tortuosity was severe (90 degrees) and
embolic protection devices could not be placed. In one
patient, this resulted in distal emboli, stroke, and the one
death.
DISCUSSION
CAS is an emerging procedure that has been used
increasingly in recent years.25-29 However, current ran-
domized clinical trial data contrasting the efficacy of CAS
and CEA are not available in conventional risk populations,
and randomized (level 1) data that establish the efficacy of
CEA versus medical management are not available for
individuals aged 80 years or older. This lead-in phase of
CREST was designed to assess the competency of individ-
ual center operators and to allow them to pass through a
credentialing phase using the CREST protocol with em-
bolic protection devices.
In this report, 30-day stroke and death among the 749
CAS patients studied was notable in that octogenarians had
a significantly increased rate of 12.1%. This was significantly
above the rates for patients aged 70 to 79 (5.3%), 60 to 69
(1.3%), and less than 60 (1.7%). These data are unique
because no other trials or registries have been completed
for CAS or CEA in which elderly patients per protocol have
been examined by neurologists preprocedure, at 24 hours,
and at 30 days post-revascularization.
Analyses of Medicare data bases,16,17 in contrast, have
demonstrated increasing morbidity and mortality among
patients older than 75 or 80 years, reporting three- and
fourfold increases in mortality.16 In another analysis of
1160 CEAs performed at 12 academic medical centers,
Goldstein30 reported no increased incidence of periopera-
tive strokes or death among symptomatic patients older
than 75 years; however, stroke and death rates were signif-
icantly higher among asymptomatic patients in this age
group.31 Conversely, observational surgical reports on
12 (
5.94
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80 years or older confirmed comparability between 30-day
stroke and death rates of the elderly population and other
patients in their series. The 30-day stroke and death rates
for octogenarians ranged from 1.9% to 4.4%, whereas sim-
ilar data on younger patients was 1.7% to 4.2%.
No series reported that complications were significantly
higher for octogenarians. In addition, Perler and col-
leagues15 analyzed the results of an assessment of 9918
elective CEA procedures performed in 48 hospitals (1990
to 1995) in the state of Maryland. These authors reported
30-day stroke and death rates of 1.3% in patients 80 years of
age or older (n  1036), which was not significantly
different from the overall rate of 1.2% for younger patients.
Although increasing medical complexity resulted in in-
creased perioperative mortality and stroke rates, this was
not directly related to age.
These studies were not designed or powered to detect
the independent effects of age upon periprocedural safety,
however. Consequently, surgeons have been extremely
cautious in their selection of patients for operation, partic-
ularly among the group with asymptomatic stenosis, and
have reported results that are essentially comparable to
other age categories.6-14
Data on carotid artery stenting among elderly patients
is modest and not directly comparable to the CREST
lead-in data. However, Chastain and colleagues19 reported
30-day stroke, myocardial infarction, and a death rate of
25% among 24 octogenarians compared with 8.2% for 158
patients aged less than 80 years. Subsequently, this group
documented a rate of 16% among 63 octoganerians20;
however, this was later reduced to 8.5% among 47 pa-
tients32 with the use of neuroprotection. No major strokes
or fatal strokes were observed in the group that received
cerebral protection.
Shawl and colleagues33 reported on 42 octogenarians
Table IV. Death or stroke within 30 days of stent proced
Total Oc
N 749
Death within 30 days 6 (0.80)
Stroke within 30 days 30 (4.01)
Death or stroke within 30 days 33 (4.41)
Table V. Impact of age on risk of stroke and death (30-da
Age strata N
Events
N (%)
Unadjusted
(P.0006)
Adjusted
symptomatic
(P  .001
60 120 2 (1.7%) 1.0 (ref) 1.0 (ref)
60-69 229 3 (1.3%) 0.78 (0.13-4.75) 0.79 (0.13-4
70-79 301 16 (5.3%) 3.31 (0.75-14.63) 3.14 (0.71-1
80 99 12 (12.1%) 8.14 (1.78-37.30) 7.82 (1.70-3in a group of 170 consecutive high-risk patients who weretreated with balloon expandable stents without cerebral
protection devices. The 30-day stroke rate was 2.9%, with
no deaths observed. No differences were reported in com-
plications among octogenarians and younger patients.
Whitlow34 reported the results of neuroprotection in a
multicentered registry of 305 CAS patients, 28% of whom
were more than 80 years old. The 30-day rate of stroke,
myocardial infarction, or death was 7.2%, and complica-
tions were not significantly increased among octogenarians.
Although emboli protection did not favorably reduce
the complication rates among octogenarians in this interim
analysis of the CREST lead-in series, a separate interim
report on 413 cases from the CREST lead-in series through
April 2003 showed a trend toward reduced stroke rates
with use of protection.35 Furthermore, in the current re-
port, tortuosity of the distal carotid arteries led to an
inability to deliver an antiembolic device, resulting in major
stroke and death in one elderly patient. Use of emboli
protection is strongly recommended, particularly in octo-
genarians. In a recent multicentered review by Kastrup and
colleagues,36 2357 CAS procedures with use of protection
were compared with 839 procedures without protection.
The combined stroke and death rate for cases with emboli
protection was 1.8%; without protection it was 5.5%, which
was a significant difference (P .001). If emboli protection
cannot be achieved, the CREST IMC currently recom-
mends that the CAS procedure should be terminated and
the patient referred for CEA.
The 12.1% stroke and death rate among octogenarians
in CREST is comparable to some previous reports. An
analysis of narratives from octogenarians in CREST sug-
gests that hemodynamic instability, particularly bradycardia
and hypotension on balloon dilatation, may have contrib-
uted to over half of the complications. This emphasizes the
need for greater care in the preprocedural and postproce-
arians (%) Non-octogenarians (%) P
13.22) 650 (86.78)
2.02) 4 (0.62) 0.1441
12.12) 18 (2.77) 0.0001
12.12 21 (3.23) 0.0001
Odds Ratio (95% CI)
s
Adjusted for
protection device
(P .0006)
Adjusted for
percent stenosis
(P .0006)
Adjusted for
gender
(P .0006)
1.0 (ref) 1.0 (ref) 1.0 (ref)
0.79 (0.13-4.78) 0.82 (0.14-4.99) 0.78 (0.13-4.75)
) 3.30 (0.75-14.60) 3.47 (0.78-15.36) 3.31 (0.75-14.62)
) 8.16 (1.78-37.44) 8.52 (1.85-39.22) 8.15 (1.78-37.39)ure
togen
99 (
2 (
12 (y)
for
statu
0)
.77)
3.99dural monitoring of vital signs, as well as in the selection of
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balloon inflation.
These results prompted the CREST Interventional
Management and Executive Committees to recommend to
the NIH-appointed Data and Safety Board, and it con-
curred, that octogenarians no longer be included in the
lead-in phase of the trial. However, because the random-
ized trial is recruiting conventional-risk patients, octoge-
narians will continue to be included provided that periodic
evaluations of stopping orders on this group by the Statis-
tical Analysis Center are not exceeded.
Octogenarians should be considered high-risk patients
for CAS stenting. Randomized trial data are needed to
compare the CAS vs CEA peri-procedural risk of stroke and
death by age. Pending results from randomized studies,
care should be exercised in selecting octogenarians for
CAS.
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Dr Bruce Perler (Baltimore, Md). I believe CREST will be
one of the seminal investigations of our time, and all of us are
indebted to Dr Hobson for his leadership and contributions in this
area.
While I believe carotid stenting is here to stay, the procedure
currently is being supported largely by registry data and industry-
sponsored trials with data that are typically presented in the lay
press rather than in the peer-reviewed literature. Although an FDA
panel recently recommended approval of stents for high-risk pa-
tients, that deliberation was highly politicized and the vote was
nearly evenly split down the middle. I think we need good science.
We clearly need CREST.
Carotid stenting has a role to play in high-risk patients. The
conundrum is: how do we define high risk? Historically, we have
assumed that very elderly patients are at increased risk for compli-
cations with carotid endarterectomy. A number of studies, includ-
ing a population-based series of nearly ten thousand cases we
reported for Maryland, demonstrated that the elderly undergo this
operation with outcomes comparable to younger patients.
Carotid endarterectomy is a safe procedure in our most elderly
patients and that’s good news because, as we’ve heard this morn-
ing, apparently carotid stenting is not.
In the lead-in phase of CREST, the stroke and death rate
among octogenarians was twelve percent, and unrelated to symp-
toms, degree of stenosis or confounding clinical issues. Octogenar-
ians tended to have more tortuous vessels that precluded safe
placement of a protection device in two cases, and the majority of
the octogenarians who suffered strokes also experienced hemody-
namic instability with balloon inflation. And that leads to my three
questions.
First, Dr Hobson, could you characterize the etiology of the
strokes among the octogenarians? Were they largely watershed
events related to that hemodynamic instability, or did these pa-
tients suffer largely embolic strokes?
Secondly, and perhaps more importantly, could you charac-
terize the etiology of the strokes in the younger patients? And was
vessel tortuosity or hemodynamic instability a cause of those
strokes in those younger patients? In other words, is advanced age
simply a marker for other factors that contribute to strokes in these
patients?
And finally, in the manuscript you pointed out that you would
no longer include octogenarians in the lead-in phase, but would
continue to randomize them in the trial. I was hoping you might
elaborate on the rationale for that policy, because it does seem
somewhat in conflict.
Dr Robert Hobson, II.We are familiar with your group and
its study of the Maryland database that so elegantly pointed out
that endarterectomy was safe in a very large database of patients.
With regard to your questions, embolic phenomena ac-
counted for most of the strokes in the octogenarian group, butabout half of the strokes, five in number, were associated with
hemorrhage. Tom Brott, the co-PI in neurology, has studied the
imaging reports on these patients and believes that elderly patients
are more susceptible not only to embolic events because of the
tortuosity of their anatomy but also possibly to hemorrhagic
influence because of the heparin and the significant antiplatelet
therapy that is on board.
In the younger patients, the incidence of hemorrhage was less
and the incidence of embolic ischemic strokes was higher, suggest-
ing that although we didn’t directly show benefit for the neuro-
protection, intuitively we think that that is reducing the number of
strokes in younger patients and may ultimately lead to better
control of strokes in the octogenarians.
The Data Safety and Monitoring Board at the NIH, when
presented with the CREST data, agreed with the executive com-
mittee, which included Dr Gary Rubin, the chair of our interven-
tional management committee, that we should discontinue the
enrollment of patients to the lead-in phase. We did not ask for, nor
did we receive, a similar judgment for the randomization phase.
Our rationale, Bruce, was that we think the randomization group is
a much more conventional, low-risk group of patients.
However, at the insistence of the Data Safety and Monitoring
Board, George Howard, the biostatistician for CREST, is looking
at that blinded data and will keep the DSMB, as well as the
investigators, informed of any stoppage orders on octogenarians.
So I think it’s a safe and a reasonable decision that the investigative
team, in conjunction with the objective oversight Data Safety and
Monitoring Board, has made.
Dr Gregorio Sicard (St. Louis, Mo). Do you have any
information of the timing of the stroke as it is related to the
insertion of the protection device? And in how many of these
patients that had strokes did you retrieve debris from your filter?
Dr Hobson. There was a great deal of concern among the
investigators that the first generation ACCUNET device, because
of its higher profile, would increase the incidence of ischemic
strokes by simply having to be pre-dilated, in many instances, up to
twenty percent before its deployment. We have been unable to
prove that objectively. And although all of us are embracing the RX
technique with its lower profile, we still have been unable to relate
the incidence of embolic stroke to the larger profile of the neuro-
protection device.
The second question had to do with debris collection, and this
is not being studied in CREST. It was a budgetary issue and the
collection of the neuroprotection devices for referral to pathology
for review, although a meritorious suggestion, was not included in
the protocol. Anecdotally, at our own center, we find particulate
material in about twenty percent of our devices. And the incidence
of device recovery, again, doesn’t appear to be directly related to
the incidence of neurological events.
